CSPC Pharmaceutical shares rise 4.6% after FDA nod for herpes zoster vaccine trial

CSPC Pharmaceutical Group climbed 4.6% to HK$9.91, its highest since August 26, after the company said its herpes zoster vaccine SYS6052 obtained U.S. FDA approval to conduct clinical trials in the US; the stock was also on track for its biggest one-day gain since September 21.